CAS: 19774-82-4; (2-Butylbenzofuran-3-yl)(4-(2-(Diethylamino)Ethoxy)-3,5-Diiodophenyl)Methanone Hydrochloride

上下游产品

2-chloro-N,N-diethylethylamine hydr°Chloride 2-n-butyl-3-(3',5'-diiodo-4'-hydroxybenzoyl)benzofuran 2-n-butylbenzo[b]furan methyl 2-(2-formylphenoxy)hexanoate4-Hydroxyamiodarone (+/-)-{4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}[2-(3-hydroxybutyl)benzofuran-3-yl]methanone hydr°Chloride

2-丁基苯并呋喃置于甲醇,Iron(III) Chloride,碘,Potassium Carbonate,Sodium Hydroxide体系中,用 水,1,2-二氯乙烷,甲苯 用作溶剂,化学反应 17.0H,反应生成盐酸胺碘酮
参考文献:一种制备盐酸胺碘酮的方法
标题:一种制备盐酸胺碘酮的方法
摘要:本发明公开一种制备盐酸胺碘酮的方法,包括:以2‑丁基苯并呋喃和对乙酰氧基苯甲醛为原料,在lewis酸催化以及加热条件下发生aldol反应,产物在碘和碱存在的条件下同时发生羟基氧化,脱乙酰基以及碘代反应,之后产物和n,N‑二乙基氯乙胺反应,成盐,得到盐酸胺碘酮.该方法只需要催化量lewis酸的使用,不需要强酸性氯化铝的参与,反应条件更加温和,副产物少,易于后处理,三废大大减少;整个路线的操作简单,所用试剂都便宜易得,无毒害,非常适用于工业化生产.

专利信息

专利号:US-11390890-B2
优先权日:2015-02-15
标 题:Dibasic organic acid producing strain and preparation and application of same
发明人：TIAN CHAOGUANG; LI JINGEN; LONG CHUANNAN; SUN TAO; LIN LIANGCAI; XU JING; LIU QIAN; JI JINGXIAO; SUN WENLIANG; MA YANHE
权利人:TIANJIN INST IND BIOTECHNOLOGY CAS
摘要:Provided are an engineered strain for synthesizing a dibasic organic acid and preparation and application of same. The engineered strain introduces or up-regulates expression of a positive regulator gene for synthesis of a dibasic organic acid, and/or down-regulates expression of a negative regulator gene for synthesis of a dibasic organic acid, as compared with the origin strain of the engineered strain, the producing capability for producing the dibasic organic acid is improved. The dibasic organic acid comprises malic acid, succinic acid, fumaric acid, oxaloacetic acid, glutaric acid, and adipic acid; the expression product of the positive regulator gene comprises aspartate aminotransferase, glutamic acid-aspartate transporter, C4-dicarboxylic acid transporter, pyruvate carboxylase and malate dehydrogenase, glucose transporter; the expression product of the negative regulatory gene comprises succinyl-CoA synthase, and malic acid-alpha ketoglutarate transporter, and the original strain comprises Myceliophthora thermophila, Thielavia terrestris, Aspergillus , and Rhizopus.

专利号:US-6187756-B1
优先权日:1996-09-05
标 题 :Composition and methods for treatment of neurological disorders and neurodegenerative diseases
发明人：LEE ROBERT K K; WURTMAN RICHARD J
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:It has been discovered that the stimulation of β-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising β-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by β-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of β-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

专利号:US-6469055-B2
优先权日:1996-09-05
标题 :Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
发明人：LEE ROBERT K K; WURTMAN RICHARD J
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:It has been discovered that the stimulation of β-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising β-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by β-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of β-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

专利号:US-2007203079-A1
优先权日:2005-11-21
标题:Methods of using small molecule compounds for neuroprotection
发明人：CALDWELL GUY A; CALDWELL KIM A; CAO SONGSONG
权利人:CALDWELL GUY A; CALDWELL KIM A; CAO SONGSONG
摘要:Methods are provided for preventing neurodegeneration and neuronal loss by administering compositions comprising small molecule compounds with the effect of preventing neurodegeneration and neuronal loss. In one aspect of the invention, the methods and compositions are also useful for treating neurodegenerative diseases. Small molecule compounds provide an important treatment option because of their stability, ease of use in both manufacture and formulation, ease of administration, and patient compliance. The small molecule compound compositions of the present invention may include topoisomerase II inhibitors, bacterial transpeptidase inhibitors, calcium channel antagonists, cyclooxygenase inhibitors, folic acid synthesis inhibitors, or sodium channel blockers and functional analogues thereof that have an effect on neurodegeneration. The compositions of the present invention may be administered prophylactically before the onset of clinical symptoms or after clinical symptoms of a neurodegenerative disease have manifested.

专利号:CN-114671836-B
优先权日:2021-12-30
标题 :Synthesis method of amiodarone impurity C

专利号:CN-111747913-A
优先权日:2020-07-15
标 题 :Synthesis method of deuterated amiodarone hydrochloride